<DOC>
	<DOC>NCT01480674</DOC>
	<brief_summary>This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without progression for at least three years. Patients will be followed prospectively for one year.</brief_summary>
	<brief_title>An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patients, &gt;/= 18 years of age HER2positive metastatic breast cancer or locally advanced breast cancer Systemic treatment included Herceptin as 1st line therapy Without progression for at least 3 years after the beginning of Herceptin treatment Alive or not alive and treated or not treated with Herceptin at the time of inclusion Disease progression &lt;3 years after beginning 1stline therapy with Herceptin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>